Stay updated on Safety and Efficacy of MEDI0457 and Durvalumab in HPV+ HNC Clinical Trial
Sign up to get notified when there's something new on the Safety and Efficacy of MEDI0457 and Durvalumab in HPV+ HNC Clinical Trial page.

Latest updates to the Safety and Efficacy of MEDI0457 and Durvalumab in HPV+ HNC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe clinical trial record for the MEDI0457 and durvalumab study is now displayed, including its study design, eligibility criteria, locations, outcome measures, and posted documents, instead of an error page.SummaryDifference73%

- Check18 days agoChange DetectedThe footer revision label changes from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check25 days agoChange DetectedA site-wide NIH notice about terminology changes during the transition from “Artificial Intelligence” to “Super Intelligence” appears above the ClinicalTrials.gov page.SummaryDifference1%

- Check32 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.1 to v3.7.2 while the study page remained inaccessible.SummaryDifference0.2%

- Check39 days agoChange DetectedThe footer revision changes from v3.7.0 to v3.7.1; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check52 days agoChange DetectedThe page now displays a 403 Forbidden error message with a 403 header and a Home link, replacing the expected study record content.SummaryDifference0.5%

Stay in the know with updates to Safety and Efficacy of MEDI0457 and Durvalumab in HPV+ HNC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety and Efficacy of MEDI0457 and Durvalumab in HPV+ HNC Clinical Trial page.